Xilio Therapeutics Finalizes Reverse Stock Split Proposal to Avoid Nasdaq Delisting

summarizeSummary

Xilio Therapeutics filed a definitive proxy statement, setting a special meeting for February 23, 2026, to seek stockholder approval for a reverse stock split (1-for-2 to 1-for-30) aimed at maintaining its Nasdaq listing.

check_boxKey Events

• Special Meeting Scheduled for Reverse Split Vote

  A special meeting of stockholders is scheduled for February 23, 2026, to vote on an amendment to the company's certificate of incorporation to effect a reverse stock split.

• Reverse Stock Split Ratio Proposed

  Stockholders will vote on a reverse stock split at a ratio within the range of 1-for-2 to 1-for-30, with the exact ratio to be determined by the board of directors.

• Critical for Nasdaq Listing Compliance

  The primary purpose of the reverse stock split is to increase the per share market price to meet Nasdaq's minimum bid price requirement and avoid delisting by the March 30, 2026 deadline.

• Board Unanimously Recommends Approval

  The board of directors unanimously recommends that stockholders vote 'FOR' the adoption and approval of the reverse stock split proposal.

auto_awesomeAnalysis

This definitive proxy statement finalizes the terms for a special stockholder meeting on February 23, 2026, to vote on a reverse stock split. The company, with its stock trading significantly below $1.00, is urgently seeking approval for a reverse split (1-for-2 to 1-for-30) to meet Nasdaq's minimum bid price requirement by the March 30, 2026 deadline. While a reverse split is a critical step to avoid delisting and maintain market access, it does not address underlying operational or financial challenges. Investors should note the board's unanimous recommendation, highlighting the necessity of this action, but also be aware that there is no guarantee of sustained compliance or improved market perception post-split.